Fante, who currently serves as Innocoll's chief commercial officer and head of business development, succeeds Anthony Zook, who retired from his role as Innocoll CEO.
Fante joined Innocoll in 2015 as chief commercial officer and head of business development.
In this role, he built an experienced, highly talented commercial team to prepare the company for commercialisation and also led all business development activities, including Innocoll's acquisition by Gurnet Point.
Prior to Innocoll, Fante spent nearly twenty years at AstraZeneca in the United States, serving in a variety of leadership roles, including president, US, CEO of North America and Regional vice president of the Americas.
He also formerly served as an independent director for Inhibikase Therapeutics, Inc. Fante graduated from Princeton University with a B.A. in Biology and received an MBA from the University of North Carolina at Chapel Hill.
Innocoll is a specialty pharmaceutical company focused on the development and commercialisation of pharmaceutical technologies Its current late-stage product pipeline is focused on addressing patient needs for postsurgical pain management.
Gurnet Point Capital is a healthcare fund founded by Ernesto Bertarelli and led by Chris Viehbacher, who.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer